Neal Shonnard, MD
Orthopaedic Surgery of the Spine · Puyallup, WANPI 1932135795
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $30,317 of the $39,029 with a category attached, or 77.7%. Globus Medical accounts for 77.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $11,124 and has fallen 76.1% since, to $2,663 in 2025.
Across 75 payments — averaging $520.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Globus Medical$30K
- Cerapedics Inc.$5K
- Boston Scientific$673
- Stryker$538
- Medtronic$457
- Abbott$303
- plus $2K from 18 others
What the payments were for
- Royalty or licence$30,31778%
- Consulting fees$4,80012%
- Food & beverage$3,91210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Globus Medical | 25 | $30,328 |
| Cerapedics Inc. | 2 | $4,986 |
| Boston Scientific | 6 | $673 |
| Stryker | 7 | $538 |
| Medtronic(2 entities) | 6 | $457 |
| Abbott | 2 | $303 |
| Pacira Pharmaceuticals Incorporated | 3 | $273 |
| Biotronik NRO, Inc. | 2 | $212 |
| Heron Therapeutics, Inc. | 3 | $182 |
| Zimmer Biomet | 1 | $139 |
| UCB, Inc. | 3 | $130 |
| Xtant Medical Inc | 1 | $113 |
| Medical Device Business Services, Inc. | 1 | $112 |
| Si-bone, Inc. | 1 | $111 |
| Carbofix Spine Inc | 1 | $103 |
| Relievant Medsystems, Inc. | 1 | $97 |
| Orthofix Medical, Inc. | 1 | $89 |
| Surgalign Spine Technologies, Inc. | 1 | $58 |
| Amgen | 3 | $43 |
| Flowonix Medical Incorporated | 1 | $30 |
| Radius Health, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
| Fidia Pharma USA Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Plymouth$30,317
- I-FACTOR PEPTIDE ENHANCED BONE GRAFT$4,800
- GENERAL PAIN MANAGEMENT$342
- GENERAL K2M PRODUCT DISCUSSION$191
- i-FACTOR Putty$186
- ETERNA$171
- INTELLIS ADAPTIVESTIM$171
- IVS - MULTIGEN RF$150
- IVS - IVAS$150
- KYPHON EXPRESS II KYPHOPAK TRAY$142
- Mobi-C$139
- BIOTRONIK$132
- PROCLAIM$132
- APONVIE$125
- EXPAREL$112
- iFuse Implant$111
- WaveWriter Alpha Prime 16$104
How this compares
$39,029 in reported general payments places this provider in the 75th percentile of 61 orthopaedic surgery of the spine providers in Washington.
See all orthopaedic surgery of the spine providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alprazolam | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery of the spine in Puyallup
- Antoine TohmehSpokane$4.3M
- Rajiv SethiSeattle$2.9M
- Mark FreebornKirkland$1.8M
- Alireza AnissipourEverett$598K
- Richard BransfordSeattle$413K
- Jens ChapmanSeattle$394K
- Venu NemaniSeattle$199K
- Philip LouieSeattle$132K
- John ShusterSpokane$124K
- Nicholas SpinaSeattle$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.